Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
View/ Open
Author
Coelho, Teresa
Merlini, Giampaolo
Bulawa, Christine E.
Fleming, James A.
Judge, Daniel P.
Kelly, Jeffery W.
Maurer, Mathew S.
Planté-Bordeneuve, Violaine
Labaudinière, Richard
Mundayat, Rajiv
Riley, Steve
Lombardo, Ilise
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1007/s40120-016-0040-xMetadata
Show full item recordCitation
Coelho, T., G. Merlini, C. E. Bulawa, J. A. Fleming, D. P. Judge, J. W. Kelly, M. S. Maurer, et al. 2016. “Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.” Neurology and Therapy 5 (1): 1-25. doi:10.1007/s40120-016-0040-x. http://dx.doi.org/10.1007/s40120-016-0040-x.Abstract
Transthyretin (TTR) transports the retinol-binding protein–vitamin A complex and is a minor transporter of thyroxine in blood. Its tetrameric structure undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to aggregate or to become amyloidogenic. Mutations in the TTR gene generally destabilize the tetramer and/or accelerate tetramer dissociation, promoting amyloidogenesis. TTR-related amyloidoses are rare, fatal, protein-misfolding disorders, characterized by formation of soluble aggregates of variable structure and tissue deposition of amyloid. The TTR amyloidoses present with a spectrum of manifestations, encompassing progressive neuropathy and/or cardiomyopathy. Until recently, the only accepted treatment to halt progression of hereditary TTR amyloidosis was liver transplantation, which replaces the hepatic source of mutant TTR with the less amyloidogenic wild-type TTR. Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis. Tafamidis is the first pharmacotherapy approved to slow the progression of peripheral neurologic impairment in TTR familial amyloid polyneuropathy. Here we describe the mechanism of action of tafamidis and review the clinical data, demonstrating that tafamidis treatment slows neurologic deterioration and preserves nutritional status, as well as quality of life in patients with early-stage Val30Met amyloidosis. Electronic supplementary material The online version of this article (doi:10.1007/s40120-016-0040-x) contains supplementary material, which is available to authorized users.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919130/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822117
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)